Platelet caspase-1 and Bruton tyrosine kinase activation in patients with COVID-19 is associated with disease severity and reversed in vitro by ibrutinib.
Livia ClaudeFrédéric MartinoPatricia HermandBassel ChahimPierre-Marie RogerMarie de BourayneYohann GarnierBenoit TressièresYves ColinCaroline Le Van KimMarc RomanaVéronique BacciniPublished in: Research and practice in thrombosis and haemostasis (2022)
Our results show that caspase-1 and BTK activation are related to disease severity and suggest the therapeutic hope raised by ibrutinib in the treatment of COVID-19 by reducing the procoagulant state of the patients.
Keyphrases
- tyrosine kinase
- epidermal growth factor receptor
- end stage renal disease
- cell death
- ejection fraction
- sars cov
- coronavirus disease
- newly diagnosed
- chronic kidney disease
- induced apoptosis
- peritoneal dialysis
- chronic lymphocytic leukemia
- patient reported outcomes
- signaling pathway
- oxidative stress
- smoking cessation
- replacement therapy